Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FLT3 |
Variant | amp |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | FLT3 amplification indicates an increased number of copies of the FLT3 gene. However, the mechanism causing the increase is unspecified. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04491084 | Phase Ib/II | CDX-1140 + CDX-301 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy (FLT3) | Terminated | USA | 0 |
NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT04116541 | Phase II | Alectinib Cabozantinib Ribociclib + Siremadlin | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
NCT04631744 | Phase II | Cabozantinib | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Recruiting | USA | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT05010200 | Phase I | CDX-301 + PGV 001 + Poly ICLC PGV 001 + Poly ICLC | The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PGV-Prostate) | Active, not recruiting | USA | 0 |
NCT04536077 | Phase II | CDX-1140 + CDX-301 CDX-1140 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Terminated | USA | 0 |